In establishing restorative agents for COVID-19, scientists learned from the lessons of past infections, from HIV to Ebola to even influenza, experts at an NIH webinar said.
Clinical agents in development for SARS-CoV-2 consist of antivirals and host targeted/immunomodulators, along with neutralizing monoclonal antibodies. And randomized trials are still the best way to determine whether they work, professionals said.
The Accelerating COVID-19 Restorative Interventions and Vaccines(ACTIV) series of trials are public-private collaborations. ACTIV-1 studies host-targeted immune modulators, ACTIV-2 and ACTIV-3 focuses on neutralizing antibodies and oral antivirals, ACTIV-4 targets anticoagulants and antiplatelet drugs, and ACTIV-5 (the “Huge Result Trial”), a phase II evidence of idea study looks at “several appealing treatments.”
However antivirals are still desperately needed, as just remdesivir (Veklury) has been authorized by the FDA to deal with COVID-19
Anthony Fauci, MD, director of the National Institute of Allergy and Contagious Diseases (NIAID), talked about prior experience in studying the duplication cycle for the HIV infection. He included that discovering “all susceptible points of intervention” eventually led to a host of antiretroviral therapies versus the illness, including nucleoside/nucleotide reverse tran